Google's December 2025 core update is now done rolling out, it took 18 days and 2 hours to complete. The core update started on December 11, 2025 at around 12:25 pm ET and ended on December 29, 2025 ...

Core Scientific Inc. (NASDAQ:CORZ) is one of the best bitcoin mining stocks to buy according to Hedge Funds. At close of play on December 24, the consensus ratings project a bullish market view for ...

The expert panel identified 6 core competencies for medical cannabis education and rated them for comprehensiveness using a 5-point Likert scale. Researchers developed a consensus statement to address ...

Diccon Hyatt is an experienced financial and economics reporter. He's written hundreds of articles breaking down complex financial topics in plain language, emphasizing the impact that economic ...

“Just as President Trump told Americans last night: inflation continues to fall, wages continue to rise, and America is trending towards a historic economic boom. Today’s report shows that inflation ...

Google's December 2025 core update leads this week's SEO Pulse, alongside Preferred Sources expansion and social insights in Search Console. The December 2025 core update is the main story this week.

Core & Main Inc (NYSE: CNM) reported better-than-expected earnings for the third quarter on Tuesday. Core & Main reported quarterly earnings of 89 cents per share which beat the analyst consensus ...

The Commerce Department reported Friday that core prices increased by 2.8 percent compared to September of last year, excluding food and energy costs. The monthly rise in costs was measured at 0.2 ...

Dec. 5 (UPI) --A U.S. Department of Commerce report Friday indicated inflation in September was lower than anticipated. The delayed report by the department's Bureau of Economic Analysis due to the ...

CNBC’s Rick Santelli joins ‘Squawk on the Street’ with the latest economic data to cross the tape. Got a confidential news tip? We want to hear from you. Sign up for free newsletters and get more CNBC ...

Almost exactly one year ago, Janux Therapeutics unveiled early data for its investigational T-cell engager that wowed investors and analysts alike. But the biotech’s newest update has failed to garner ...